These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 8632312)

  • 1. Pharmacological characterization of A-127722: an orally active and highly potent ETA-selective receptor antagonist.
    Opgenorth TJ; Adler AL; Calzadilla SV; Chiou WJ; Dayton BD; Dixon DB; Gehrke LJ; Hernandez L; Magnuson SR; Marsh KC; Novosad EI; Von Geldern TW; Wessale JL; Winn M; Wu-Wong JR
    J Pharmacol Exp Ther; 1996 Feb; 276(2):473-81. PubMed ID: 8632312
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological properties of J-104132 (L-753,037), a potent, orally active, mixed ETA/ETB endothelin receptor antagonist.
    Nishikibe M; Ohta H; Okada M; Ishikawa K; Hayama T; Fukuroda T; Noguchi K; Saito M; Kanoh T; Ozaki S; Kamei T; Hara K; William D; Kivlighn S; Krause S; Gabel R; Zingaro G; Nolan N; O'Brien J; Clayton F; Lynch J; Pettibone D; Siegl P
    J Pharmacol Exp Ther; 1999 Jun; 289(3):1262-70. PubMed ID: 10336515
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nonpeptide endothelin receptor antagonists. VI: Pharmacological characterization of SB 217242, a potent and highly bioavailable endothelin receptor antagonist.
    Ohlstein EH; Nambi P; Lago A; Hay DW; Beck G; Fong KL; Eddy EP; Smith P; Ellens H; Elliott JD
    J Pharmacol Exp Ther; 1996 Feb; 276(2):609-15. PubMed ID: 8632328
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacological profile of T-0201, a highly potent and orally active endothelin receptor antagonist.
    Hoshino T; Yamauchi R; Kikkawa K; Yabana H; Murata S
    J Pharmacol Exp Ther; 1998 Aug; 286(2):643-9. PubMed ID: 9694915
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacology of L-754,142, a highly potent, orally active, nonpeptidyl endothelin antagonist.
    Williams DL; Murphy KL; Nolan NA; O'Brien JA; Pettibone DJ; Kivlighn SD; Krause SM; Lis EV; Zingaro GJ; Gabel RA
    J Pharmacol Exp Ther; 1995 Dec; 275(3):1518-26. PubMed ID: 8531124
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological profile of ZD1611, a novel, orally active endothelin ETA receptor antagonist.
    Wilson C; Hunt SJ; Tang E; Wright N; Kelly E; Palmer S; Heys C; Mellor S; James R; Bialecki R
    J Pharmacol Exp Ther; 1999 Sep; 290(3):1085-91. PubMed ID: 10454481
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nonpeptide endothelin receptor antagonists. XI. Pharmacological characterization of SB 234551, a high-affinity and selective nonpeptide ETA receptor antagonist.
    Ohlstein EH; Nambi P; Hay DW; Gellai M; Brooks DP; Luengo J; Xiang JN; Elliott JD
    J Pharmacol Exp Ther; 1998 Aug; 286(2):650-6. PubMed ID: 9694916
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Receptor binding and antagonist properties of a novel endothelin receptor antagonist, TAK-044 [cyclo[D-alpha-aspartyl-3-[(4-phenylpiperazin-1-yl) carbonyl]-L-alanyl-L-alpha-aspartyl-D-2-(2-thienyl) glycyl-L-leucyl-D-tryptophyl]disodium salt], in human endothelinA and endothelinB receptors.
    Masuda Y; Sugo T; Kikuchi T; Kawata A; Satoh M; Fujisawa Y; Itoh Y; Wakimasu M; Ohtaki T
    J Pharmacol Exp Ther; 1996 Nov; 279(2):675-85. PubMed ID: 8930171
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Subtype selectivity of a novel endothelin antagonist, FR139317, for the two endothelin receptors in transfected Chinese hamster ovary cells.
    Aramori I; Nirei H; Shoubo M; Sogabe K; Nakamura K; Kojo H; Notsu Y; Ono T; Nakanishi S
    Mol Pharmacol; 1993 Feb; 43(2):127-31. PubMed ID: 8429819
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological characterization of PD 156707, an orally active ETA receptor antagonist.
    Reynolds EE; Keiser JA; Haleen SJ; Walker DM; Olszewski B; Schroeder RL; Taylor DG; Hwang O; Welch KM; Flynn MA
    J Pharmacol Exp Ther; 1995 Jun; 273(3):1410-7. PubMed ID: 7791115
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacology of A-216546: a highly selective antagonist for endothelin ET(A) receptor.
    Wu-Wong JR; Dixon DB; Chiou WJ; Dayton BD; Novosad EI; Adler AL; Wessale JL; Calzadilla SV; Hernandez L; Marsh KC; Liu G; Szczepankiewicz B; von Geldern TW; Opgenorth TJ
    Eur J Pharmacol; 1999 Feb; 366(2-3):189-201. PubMed ID: 10082200
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ro 61-1790, a new hydrosoluble endothelin antagonist: general pharmacology and effects on experimental cerebral vasospasm.
    Roux S; Breu V; Giller T; Neidhart W; Ramuz H; Coassolo P; Clozel JP; Clozel M
    J Pharmacol Exp Ther; 1997 Dec; 283(3):1110-8. PubMed ID: 9399983
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological characterization of bosentan, a new potent orally active nonpeptide endothelin receptor antagonist.
    Clozel M; Breu V; Gray GA; Kalina B; Löffler BM; Burri K; Cassal JM; Hirth G; Müller M; Neidhart W
    J Pharmacol Exp Ther; 1994 Jul; 270(1):228-35. PubMed ID: 8035319
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of a potent and selective endothelin-B receptor antagonist, IRL 2500.
    Balwierczak JL; Bruseo CW; DelGrande D; Jeng AY; Savage P; Shetty SS
    J Cardiovasc Pharmacol; 1995; 26 Suppl 3():S393-6. PubMed ID: 8587424
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacological profile of FR139317, a novel, potent endothelin ETA receptor antagonist.
    Sogabe K; Nirei H; Shoubo M; Nomoto A; Ao S; Notsu Y; Ono T
    J Pharmacol Exp Ther; 1993 Mar; 264(3):1040-6. PubMed ID: 8450448
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structure-activity relationships of a novel series of orally active nonpeptide ETA and ETA/B endothelin receptor-selective antagonists.
    Doherty AM; Patt WC; Repine J; Edmunds JJ; Berryman KA; Reisdorph BR; Walker DM; Haleen SJ; Keiser JA; Flynn MA
    J Cardiovasc Pharmacol; 1995; 26 Suppl 3():S358-61. PubMed ID: 8587414
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacology of endothelin receptor antagonists ABT-627, ABT-546, A-182086 and A-192621: ex vivo and in vivo studies.
    Wessale JL; Adler AL; Novosad EI; Calzadilla SV; Dayton BD; Marsh KC; Winn M; Jae HS; von Geldern TW; Opgenorth TJ; Wu-Wong JR
    Clin Sci (Lond); 2002 Aug; 103 Suppl 48():112S-117S. PubMed ID: 12193067
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nonpeptide endothelin receptor antagonists. VII: Binding characteristics of [3H]SB 209670, a novel nonpeptide antagonist of endothelin receptors.
    Nambi P; Pullen M; Wu HL; Lee D; Saunders D; Heys R; Aiyar N; Leber J; Elliott J; Brooks D; Ohlstein E; Ruffolo R
    J Pharmacol Exp Ther; 1996 Jun; 277(3):1567-71. PubMed ID: 8667224
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endothelin receptor antagonist activity of (R)-(-)-2-(benzo[1,3]dioxol-5-yl)-N-(4-isopropylphenylsulfonyl)-2-(6-methyl- 2-propylpyridin-3-yloxy)acetamide hydrochloride (PABSA) in rat aortic smooth muscle cells and isolated rat thoracic aorta.
    Iwasaki T; Hayasaki-Kajiwara Y; Matsuo Y; Nakajima M
    Arzneimittelforschung; 2001; 51(7):529-34. PubMed ID: 11505783
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selective endothelin A receptor antagonists. 3. Discovery and structure-activity relationships of a series of 4-phenoxybutanoic acid derivatives.
    Astles PC; Brealey C; Brown TJ; Facchini V; Handscombe C; Harris NV; McCarthy C; McLay IM; Porter B; Roach AG; Sargent C; Smith C; Walsh RJ
    J Med Chem; 1998 Jul; 41(15):2732-44. PubMed ID: 9667964
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.